Trial Profile
A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 and 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Silatecan (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 24 Jan 2012 Status changed from recruiting to completed.
- 20 Jan 2012 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 21 Sep 2010 New trial record